Novasep (Lyon, France; www.novasep.com) is building a new synthesis laboratory and a “kilo lab” for its U.S. facility. This extension will allow Novasep to offer both chemistry and purification services. It will enable Novasep to produce the initial kilogram-scale batches of synthetic molecules that are needed for biological testing and preclinical trials.
Novasep’s investment is a direct response to increasing demand from U.S. customers for closer proximity to Novasep’s contract manufacturing services that accelerate early stage development and ease production scale-up. The new laboratory will start operations in May 2016.
“The new U.S. laboratory greatly enhances Novasep’s global offering for CMO services,” says Andrew Brennan, general manager of Novasep’s US operations. “Our unique skills and expertise in highly specialized chemical and purification technologies rank us among the leaders in these fields. U.S. drug developers will benefit from our extended services that specifically target their needs.”
The new laboratory will be located at Novasep’s facility in Boothwyn, Pa., 20 minutes from Philadelphia airport. This team has provided Novasep purification development services to North American customers for more than 15 years; including screening and process development derived from Novasep’s proprietary preparative chromatography technology.
Novasep will equip the U.S. facility with reactors up to 50 L in size. The new laboratory will feature cryogenic capacities as well as standard chemistry. In terms of purification, it will provide North American customers with the complete portfolio of Novasep preparative chromatography processes, such as HPLC (Hipersep), SFC (Supersep) and state of the art evaporation. In addition, it will be equipped with all required analytical tools for PR&D (Process Research and Development), including process safety testing capabilities.